Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlormethiazole + haloperidol is a combination therapy consisting of two distinct drugs used together, primarily in the management of delirium tremens and severe alcohol withdrawal. Chlormethiazole is a sedative and hypnotic agent that acts as a central nervous system depressant, mainly by potentiating GABAergic neurotransmission, leading to its calming effects[4][1]. Haloperidol is a typical (first-generation) antipsychotic that exerts its primary effect through antagonism of dopamine D2 receptors in the brain, reducing psychotic symptoms such as hallucinations and agitation[2][7]. The rationale for combining these agents is to address both the neurovegetative (autonomic) disturbances with chlormethiazole and the psychotic features with haloperidol during acute alcohol withdrawal syndromes like delirium tremens[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlormethiazole + haloperidol.